BIIB: Diversification, disciplined investment, and pipeline execution drive growth and resilience
Management highlighted strategic diversification beyond neurology, disciplined capital allocation, and operational efficiency. Key growth drivers include a robust late-stage pipeline, expansion into nephrology and immunology, and commercial execution of new assets like felzartamab and SYFOVRE.Based…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.